Michael Null Named President of Aurora Research Institute
PALM BEACH GARDENS, Fla. – Aurora Diagnostics announced today the appointment of Michael Null as the first president of the Aurora Research Institute, a division of Aurora dedicated to partnering with institutions to advance medical research. Mr. Null will report directly to Aurora Diagnostics Chairman, Chief Executive Officer and President Daniel D. Crowley.
Mr. Null assumes the new position after serving as Aurora’s Executive Vice President of Sales & Marketing and working for the last two years in the launch and development of the Aurora Research Institute, which can provide researchers with access to millions of well characterized tissue samples.
Aurora started the Institute amid growing demand for human biomaterials by academic, government and private researchers who are trying to advance medical research and development in the area of personalized medicine. ARI has access to a national hospital and physician network, over 120 pathologists in all subspecialty areas, and a network of laboratory professionals to help determine the efficacy of new products.
“In the two years since it started, Michael has provided leadership to grow the Aurora Research Institute from an idea to a key partner for researchers around the world,” Mr. Crowley said. “The positioning of the Aurora Research Institute as a distinct unit with a dedicated leader of Mike’s caliber will enable it to develop the systems and infrastructure it needs to support the significant growth we see ahead.”
“I am excited to be able to devote my full attention to the Aurora Research Institute,” Mr. Null said. “The Institute is doing great work, currently partnering with pharmaceutical and biotech companies in North America, Europe, and Asia. We also have pre-clinical and clinical trials underway, as well as biospecimen procurement projects with hospital lab partners to ethically provide biospecimens for research.”
Before joining Aurora in 2007, Mr. Null previously worked for Asterand plc, Renaissance Worldwide Inc. and DIANON Systems Inc. He came to Aurora from Asterand, a leading provider of human tissue-based research services for the pharmaceutical and biotechnology industry. Mr. Null holds a Bachelor of Science degree from Boston University.
About Aurora Diagnostics
Aurora Diagnostics is the leading independent specialized laboratory company focused on anatomic pathology at 23 locations in the United States. Employing more than 120 licensed physicians, Aurora Diagnostics provides high-quality diagnostics and testing information for the patients of its primary referral sources—dermatologists, OB/GYN professionals, gastroenterologists, urologists, general surgeons, oncologists, and for more than 60 community hospitals. For additional information regarding Aurora Diagnostics and the services it provides, please visit the company website at www.auroradx.com.
Forward Looking Statements
Certain matters discussed in this press release may constitute forward-looking statements within the meaning of federal securities laws. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors, some of which are not within the control of the Company. Aurora reports information that may be significant for investors in its filings with the Securities and Exchange Commission (SEC), and Aurora encourages investors to consult those filings.